About this episode
Gilead CEO Daniel O’Day shares details of Remdesivir’s two positive trials against Covid-19. He explains collaboration among global drugmakers, the process of finding a treatment for coronavirus, and worldwide, equitable distribution of the drug once it’s developed. CNBC’s Senior Health Science Reporter Meg Tirrell traces the history of Remdesivir, as well as the world’s response to pandemics in the past. In a conversation exclusive to Squawk Pod, Tirrell tracks the drugmakers still in the race for a Covid vaccine and treatment, and she explains covering the pandemic accurately amid rapidly evolving headlines. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.